2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5135 Outcomes of haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia not in remission: A multicenter cohort study

Zhuohui Man, N/A, Yicheng Zhang2, Jia Chen Sr, MD3, Xiaoxia Hu, MD4, Xiao-Dong Mo, MD5, Wei Shi6, Yang Cao, MD7
1 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 The First Affiliated Hospital of Soochow University, Suzhou, China, Suzhou, China
4 Shanghai Institute of Hematology National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine., Shanghai, China
5 Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China
6 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for many patients with primary refractory or relapsed AML, but optimal selection without complete remission remains uncertain. The role of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in this setting is unclear, as they are relatively rarely included in most contemporary studies of AML not in remission. We therefore evaluated survival outcomes and prognostic factors in a multicenter cohort of 192 patients with AML not in remission who underwent haplo-HSCT.

Study design

This multicenter retrospective cohort study included patients with AML who underwent haplo-HSCT while not in remission. Eligible patients had primary induction failure (PIF), non-complete remission (NCR), untreated relapse or refractory relapse (UR/RR) before transplantation. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), event-free survival (EFS), graft-versus-host disease relapse-free survival(GRFS), relapse/progression of disease(R/POD) and non-relapse mortality (NRM).

Statistical analysis

OS was estimated using the Kaplan–Meier method and compared with the log-rank test. Cumulative incidences of R/POD, NRM were estimated using competing-risk methods with Gray's test. Cox proportional hazards models were used for OS, PFS, EFS, and GRFS. Cause-specific hazards regression was used for R/POD and NRM. Variables with a univariable P value <0.10 were considered for multivariable analysis. Regression analyses were stratified by treatment center.

Results

Patient characteristics

A total of 192 patients with AML not in remission before haplo-HSCT were included. 90 patients were PIF/NCR, and 102 were UR/RR. The median age at transplantation was 43 years, and 53% of patients were male. The median pretransplant bone marrow blast percentage was 10.5%(range, 0–91). 55% of patients were classified as having adverse genetic risk. Myeloablative conditioning was used in 84% of patients.

Survival outcomes

With a median follow-up of 40 months, the median OS was 18.8 months. The 3-year probability of OS was 43.8% (95% CI, 37.1–51.8), respectively. The median PFS was 11.4 months, with 3-year PFS rates of 38.6% (95% CI, 32.1–46.4). The median EFS was 9.9 months, with 3-year EFS rates of 36.3% (95% CI, 29.9–43.9). The median GRFS was 6.8 months, with 3-year GRFS rates of 25.4% (95%CI, 19.8–32.7). The cumulative incidence of R/POD was 38.9% (95% CI, 31.8–45.8) at 3 years. The cumulative incidence of NRM was 22.6% (95% CI, 16.8–28.9) at 3 years.

Prognostic factors for OS

When analyzed as continuous variables, both older age and higher pretransplant bone marrow blast percentage were independently associated with an incremental increase in mortality risk. In addition, adverse genetic risk was independently associated with inferior OS.

Prognostic factors for R/POD

Pretransplant bone marrow blast percentage, adverse genetic risk and myeloablative conditioning were independently associated with R/POD.

Prognostic factors for NRM, PFS, EFS, and GRFS

Karnofsky performance status (KPS) ≥80 was independently associated with a lower risk of NRM, supporting the prognostic importance of patient fitness. Higher pretransplant bone marrow blast percentage and adverse genetic risk were independent adverse prognostic factors for PFS, EFS, and GRFS, whereas KPS ≥80 was independently associated with improved PFS and EFS.

Discussion

Among patients with AML not in remission before allo–HSCT, therapeutic decisions have historically been driven by categorical disease definitions. However, in this multicenter cohort of 192 patients undergoing haplo-HSCT, we observed no significant differences in OS, R/POD, or NRM between patients with PIF/NCR and those with UR/RR. This finding suggests that once patients are selected for haplo-HSCT, traditional clinical labels of “refractory” versus “relapsed” disease lose prognostic granularity.

Our data support that haplo-HSCT can achieve durable survival in selected patients with AML not in remission. Disease burden, genetic risk, age and performance status are the major determinants of outcome, supporting a risk-adapted approach in which fitter patients with controlled disease proceed directly to transplantation, whereas those with high disease burden or adverse genetics may benefit from additional cytoreduction and post-transplant relapse-prevention strategies.

Yang Cao, MD: No relevant conflicts of interest to declare.